Whalesbook
Revenue Growth vs. Profit Drop
Poly Medicure's latest financial results show a significant gap between its growing revenue and shrinking profit. The medical device maker's revenue climbed 21.3% to ₹534.5 crore in the fourth quarter. However, net profit fell 27.8% to ₹66.3 crore compared to the same period last year. This profit decline was driven by operational issues and higher costs, which compressed EBITDA margins to 20.6%, down from 27.1% year-over-year. The company announced a dividend of ₹3.5 per share.
Challenges in New Divisions
Despite strong overall revenue, the profit drop points to scaling difficulties in Poly Medicure's newer cardiology and critical care divisions. The company is planning to build three new manufacturing plants, but the costs associated with developing these complex product lines are currently outweighing their profitability. Poly Medicure's stock price fell 5% on Monday as investors reacted to the margin squeeze. The company's valuation, with a trailing P/E ratio above 45x, is considered high compared to industry peers, making it vulnerable to such results.
Risks and Valuation Concerns
Margin pressure remains a key risk for Poly Medicure in the competitive global market. Factors like export challenges and international suppliers reducing inventory have hurt recent growth. The company's focus on expansion and high-complexity products requires ongoing investment in research and development, potentially keeping net margins low in the short term. Its valuation also appears stretched compared to the median P/E for the medical equipment industry. Historically, the company has faced questions about maintaining high growth without sacrificing profitability through significant capital spending.
Long-Term Outlook
Looking ahead, Poly Medicure is focused on expanding its higher-margin cardiology and renal care product lines. Analysts are watching the company's capacity expansion plans closely, with FY27 expected to be a key year for profit growth. Management remains optimistic that new manufacturing facilities, once fully operational, will create economies of scale, leading to more stable margins and supporting long-term stock price targets.